JP2018511628A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511628A5
JP2018511628A5 JP2017553879A JP2017553879A JP2018511628A5 JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5 JP 2017553879 A JP2017553879 A JP 2017553879A JP 2017553879 A JP2017553879 A JP 2017553879A JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5
Authority
JP
Japan
Prior art keywords
seq
group
alkyl
formula
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511628A (ja
Filing date
Publication date
Priority claimed from GBGB1506393.6A external-priority patent/GB201506393D0/en
Application filed filed Critical
Publication of JP2018511628A publication Critical patent/JP2018511628A/ja
Publication of JP2018511628A5 publication Critical patent/JP2018511628A5/ja
Pending legal-status Critical Current

Links

JP2017553879A 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体 Pending JP2018511628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506393.6A GB201506393D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
GB1506393.6 2015-04-15
PCT/EP2016/058371 WO2016166299A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2018511628A JP2018511628A (ja) 2018-04-26
JP2018511628A5 true JP2018511628A5 (https=) 2019-05-09

Family

ID=53333825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553879A Pending JP2018511628A (ja) 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体

Country Status (11)

Country Link
US (1) US20180125994A1 (https=)
EP (1) EP3283118A1 (https=)
JP (1) JP2018511628A (https=)
KR (1) KR20170137115A (https=)
CN (1) CN107683146A (https=)
AU (1) AU2016249877A1 (https=)
BR (1) BR112017022256A2 (https=)
CA (1) CA2981920A1 (https=)
GB (1) GB201506393D0 (https=)
MX (1) MX2017013154A (https=)
WO (1) WO2016166299A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
HUE056289T2 (hu) 2017-02-08 2022-02-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
EP3612236A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy with an anti-cd25 antibody-drug conjugate
EP3612235A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy with an anti-psma antibody-drug conjugate
BR112019026498A2 (pt) 2017-06-14 2020-07-14 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd25
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
WO2020127573A1 (en) 2018-12-19 2020-06-25 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
MX2021011812A (es) * 2019-03-29 2021-10-22 Medimmune Ltd Compuestos y conjugados de estos.
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
AU2022333321A1 (en) * 2021-08-27 2024-04-11 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
CN116370651A (zh) * 2023-04-04 2023-07-04 上海愿智生物技术有限公司 一种抗psma抗体-药物缀合物及其制备方法和应用
WO2025145034A1 (en) * 2023-12-29 2025-07-03 T.O.A.D. Oncology Sa Anti-psma conjugates and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス, インコーポレイテッド 操作された抗体およびイムノコンジュゲート
WO2011108714A1 (ja) * 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
WO2012064733A2 (en) * 2010-11-09 2012-05-18 Medimmune, Llc Antibody scaffold for homogenous conjugation
RS57694B1 (sr) * 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
ES2680153T3 (es) * 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
KR20160047567A (ko) * 2013-08-28 2016-05-02 스템센트알엑스 인코포레이티드 조작된 항-dll3 접합체 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2018511628A5 (https=)
JP2018516243A5 (https=)
JP2018502902A5 (https=)
JP2020506951A5 (https=)
JP2020531471A5 (https=)
JP2016508130A5 (https=)
IL315310A (en) Irak degraders and uses thereof
RU2019122802A (ru) Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
JP2018516860A5 (https=)
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
JP2019502650A5 (ja) 抗ErbB2抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用
JP2020514419A5 (https=)
JP2022537158A5 (https=)
JP2014527974A5 (https=)
JP2021524449A5 (https=)
JP2016505586A5 (https=)
JP2014528466A5 (https=)
JP2014528467A5 (https=)
JP2017518040A5 (https=)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2018070648A5 (https=)
JP2013505946A5 (https=)
JP2016531915A5 (https=)
JP2017506234A5 (https=)
JP2020519643A5 (https=)